These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
SARS signature for Covid-19.pdf (600.27 kB)

Using the SARS Infection Transcriptional Signature to Identify Potential Treatments for Covid-19

submitted on 19.05.2020, 12:39 and posted on 20.05.2020, 09:40 by Richard Killick, Clive Ballard, Patrick Doherty, Gareth Williams
Gene expression data associated with viral infection of human cell lines is harnessed to define a conserved viral response signature. Drugs that tend to drive gene expression in the direction of the cellular viral response are significantly enriched for those with established antiviral activity. Transcription therefore facilitates a simple and effective filtering of candidate drugs to be put forward for bioassay validation.


Email Address of Submitting Author


King's College London


United Kingdom

ORCID For Submitting Author


Declaration of Conflict of Interest

CB reports grants and personal fees from Lundbeck and Acadia, and personal fees from Roche, Orion, GSK, Otusaka, Heptares, and Lilly outside the submitted work. GW, AG, EC, JC, DC and PD declare no conflicting interests.